Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126886 | 0.85 | TUBB1 (0.57) | TUBB1NFE2L2PTGS1MEN1POLB | |
| SCHEMBL13126951 | 0.81 | TUBB1 (0.45) | TUBB1NFE2L2MEN1POLBKMT2A | |
| SCHEMBL10069721 | 0.81 | TUBB1 (0.62) | TUBB1NFE2L2PTGS1MEN1POLB | |
| SCHEMBL10069727 | 0.80 | APP (0.52) | MEN1POLBKMT2AAPP | |
| SCHEMBL13127036 | 0.80 | TRPA1 (0.49) | TUBB1NFE2L2APPCYP1A1CYP1A2 | |
| SCHEMBL10069726 | 0.77 | CYP1A1 (0.44) | NFE2L2MEN1POLBKMT2ACYP1A1 | |
| SCHEMBL14536925 | 0.76 | CYP1A1 (0.46) | MEN1POLBKMT2ACYP1A1CYP1A2 | |
| SCHEMBL10069274 | 0.75 | NFE2L2 (0.51) | NFE2L2PTGS1MEN1KMT2ACYP1A1 | |
| SCHEMBL13822099 | 0.74 | NFE2L2 (0.35) | NFE2L2PTGS1MEN1POLBKMT2A | |
| SCHEMBL13860860 | 0.74 | PABPC1 (0.36) | NFE2L2PABPC1RAB9AEIF4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124626-B2 | Methods of treating inflammations and infections with pyridinium salts | MYCOSOL, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7820696-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | KLEIN RICHARD B | 2010-10-21 | — | — | US | disclosed |
| US-20090137639-A1 | METHODS FOR CONTROLLING FUNGI AND BACTERIA | MYCOSOL, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | MYCOSOL, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7220761-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | BLVRB, PNPO, PLPBP | TUBB1 563/4885NFE2L2 3995/4885PTGS1 2442/4885 |
| US-20090137639-A1 | METHODS FOR CONTROLLING FUNGI AND BACTERIA | PNPO, BLVRB, DPM1 | TUBB1 287/4885NFE2L2 4495/4885PTGS1 2903/4885 |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | PNPO, PLPBP, TPMT | TUBB1 906/4885NFE2L2 1044/4885PTGS1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.